Patient demographics and medical history
| Cohort . | PLAT-02 #1 . | PLAT-02 #2 . | PLAT-05 . | All . |
|---|---|---|---|---|
| Diagnosis (%) | ALL (100) | ALL (85), lymphoma (15) | ALL (100) | |
| Treatment | SCRI-CAR19v1 | SCRI-CAR19v1.5 | SCRI-CAR19x22v1 | |
| N | 43 | 75 | 23 | 141 |
| Female, % | 51 | 33 | 39 | 40 |
| Mean age at CAR T cells (range) | 11.9 (1-25) | 12.2 (1-26) | 12.4 (1-25) | 12.2 |
| Mean relapses | 1.7 | 1.5 | 1.5 | 1.5 |
| Mean HSCTs | 0.7 | 0.4 | 0.5 | 0.5 |
| CNS involvement, % | 20.9 | 20.8 | 21.7 | 21.0 |
| Neuro comorbidities, % | 65.0 | 64.0 | 47.8 | 61.7 |
| Peripheral neuropathy, % | 16.3 | 18.7 | 8.7 | 16.3 |
| TBI (no cranial boost), % | 48.9 | 19.4 | 26.3 | 29.7 |
| Cranial boost, % | 14.0 | 16.7 | 15.8 | 15.2 |
| Mean ICANS grade | 1.1 | 1.0 | 0.6 | 1.0 |
| Mean CRS grade (0-2) | 1.1 | 1.0 | 0.9 | 1.0 |
| Any ICANS, % | 44.2 | 51.4 | 39.1 | 47.1 |
| Grade ≥3 ICANS, % | 20.9 | 16.2 | 4.3 | 15.7 |
| Cohort . | PLAT-02 #1 . | PLAT-02 #2 . | PLAT-05 . | All . |
|---|---|---|---|---|
| Diagnosis (%) | ALL (100) | ALL (85), lymphoma (15) | ALL (100) | |
| Treatment | SCRI-CAR19v1 | SCRI-CAR19v1.5 | SCRI-CAR19x22v1 | |
| N | 43 | 75 | 23 | 141 |
| Female, % | 51 | 33 | 39 | 40 |
| Mean age at CAR T cells (range) | 11.9 (1-25) | 12.2 (1-26) | 12.4 (1-25) | 12.2 |
| Mean relapses | 1.7 | 1.5 | 1.5 | 1.5 |
| Mean HSCTs | 0.7 | 0.4 | 0.5 | 0.5 |
| CNS involvement, % | 20.9 | 20.8 | 21.7 | 21.0 |
| Neuro comorbidities, % | 65.0 | 64.0 | 47.8 | 61.7 |
| Peripheral neuropathy, % | 16.3 | 18.7 | 8.7 | 16.3 |
| TBI (no cranial boost), % | 48.9 | 19.4 | 26.3 | 29.7 |
| Cranial boost, % | 14.0 | 16.7 | 15.8 | 15.2 |
| Mean ICANS grade | 1.1 | 1.0 | 0.6 | 1.0 |
| Mean CRS grade (0-2) | 1.1 | 1.0 | 0.9 | 1.0 |
| Any ICANS, % | 44.2 | 51.4 | 39.1 | 47.1 |
| Grade ≥3 ICANS, % | 20.9 | 16.2 | 4.3 | 15.7 |
ALL, acute lymphoblastic leukemia; HSCTs, hematopoietic stem cell transplants; TBI, total body irradiation.